ALK-Abelló A/S: all 72 studies

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic RhinitisEnrolling by invitationNCT06151938
• The Effect of Allergic Rhinitis on Educational OutcomesRecruitingNCT05881577
• A Study in Adults With Grass Pollen-induced RhinoconjunctivitisCompletedNCT04881461Phase 3Results posted
• A Study in Children and Adolescents With Birch Pollen-induced RhinoconjunctivitisCompletedNCT04878354Phase 3Results posted
• Adolescent Mite Allergy Safety EvaluationCompletedNCT04541004Phase 3Results posted
• House Dust Mite Allergy Trial In ChildrenCompletedNCT04145219Phase 3Results posted
• Mite Asthma Pediatric Immunotherapy TrialCompletedNCT03654976Phase 3Results posted
• Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)CompletedNCT02256553Phase 4Results posted
• Evaluation of Skin Testing Reagents for Penicillin AllergyCompletedNCT01818336Phase 3Results posted
• Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)CompletedNCT01700192Phase 3Results posted
• Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)CompletedNCT01678807Phase 1Results posted
• A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)CompletedNCT01644617Phase 2Results posted
• Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced RhinitisCompletedNCT01603056Phase 3Results posted
• Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)CompletedNCT01549340Results posted
• A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)CompletedNCT01535118Results posted
• A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)CompletedNCT01469182Phase 3Results posted
• An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense ImmunotherapyCompletedNCT01454531Phase 2/3Results posted
• A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)CompletedNCT01385371Phase 3Results posted
• Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)CompletedNCT00978029Phase 2Results posted
• Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)CompletedNCT00783198Phase 2/3Results posted
• Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)CompletedNCT00770315Phase 2/3Results posted
• Efficacy of SLITone in House Dust Mite Allergic PatientsCompletedNCT00633919Phase 2/3Results posted
• Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)CompletedNCT00562159Phase 3Results posted
• Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)CompletedNCT00550550Phase 3Results posted
• Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With HayfeverCompletedNCT00310466Phase 3Results posted
• A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65CompletedNCT07060885Phase 3
• Observational Study of Allergic Rhinitis in ChildrenCompletedNCT05655858
• Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and AsthmaCompletedNCT05476484
• Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut AllergyCompletedNCT05440643Phase 1/2
• A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure ChamberTerminatedNCT04176185Phase 3
• Impact of AIT on Allergic Rhinitis and AsthmaCompletedNCT04125888
• N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in FranceCompletedNCT03746860
• A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure ChamberCompletedNCT02481856Phase 2
• Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®CompletedNCT02437786Phase 4
• Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge ChamberCompletedNCT02166268Phase 2
• An Open Trial to Assess the Tolerability of AVANZ® Cupressus ImmunotherapyCompletedNCT02069535Phase 2
• An Open Trial to Assess the Tolerability of AVANZ® Salsola ImmunotherapyCompletedNCT02065856Phase 2
• Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With JextCompletedNCT01887405Phase 4
• Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral LyophilisateCompletedNCT01854736Phase 4
• A Trial Evaluating Tolerability of Grazax Treatment in Combination With AntihistamineCompletedNCT01740284Phase 3
• A Dose Response Evaluation of SLITone Ultra HDM Mix ImmunotherapyCompletedNCT01728298Phase 2
• Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen RhinoconjunctivitisCompletedNCT01728285Phase 3
• A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy TabletCompletedNCT01675791Phase 2
• An Open Trial to Assess the Tolerability of AVANZ Olive ImmunotherapyCompletedNCT01674595Phase 2/3
• An Open Trial to Assess the Tolerability of AVANZ Mite Mix ImmunotherapyCompletedNCT01568190Phase 2/3
• A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy TabletCompletedNCT01454544Phase 3
• Avanz Phleum Pratense Maintenance DoseCompletedNCT01438827Phase 2/3
• House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of AsthmaCompletedNCT01433523Phase 3
• Tolerability of Grazax in Patients With Hayfever in Real Life SettingsCompletedNCT01433510Phase 4
• Comparison of Different Up-dosing Schedules With Osiris Phleum PratenseCompletedNCT01425788Phase 2
• Comparison of Different Up-dosing Schedules With OsirisTerminatedNCT01240954Phase 2
• Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS BirchCompletedNCT01191359Phase 2
• Grazax Asthma PreventionCompletedNCT01061203Phase 3
• Exposure Chamber Trial With Cat ImmunotherapyCompletedNCT00987909Phase 2
• Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic PatientsCompletedNCT00857779Phase 2
• Long-term Efficacy and Safety Study With Oralgen Grass PollenCompletedNCT00824447Phase 2/3
• A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen RhinoconjunctivitisStatus unknownNCT00812799Phase 3
• Intraseasonal Short-time Up-dosing With Alutard SQ GrassesCompletedNCT00807547Phase 3
• A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax TreatmentCompletedNCT00773240Phase 3
• Efficacy and Safety of Grass Pollen Sublingual ImmunotherapyCompletedNCT00567346Phase 2/3
• Tolerability of ALK Tree TabletCompletedNCT00535639Phase 1
• Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced AsthmaCompletedNCT00492076Phase 4
• A Trial of Grazax in Subjects With HayfeverCompletedNCT00421655Phase 3
• Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass TabletsCompletedNCT00413556Phase 3
• Efficacy and Safety of Grazax in ChildrenCompletedNCT00408616Phase 3
• Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic SubjectsCompletedNCT00389363Phase 2/3
• Safety of ALK Ragweed TabletCompletedNCT00330083Phase 1
• Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic DermatitisCompletedNCT00310492Phase 3
• Tolerability of ALK Grass Tablet in ChildrenCompletedNCT00310453Phase 1
• Tolerability of Grazax-R in ChildrenCompletedNCT00298701Phase 1
• Assessment of Grazax® Treatment ComplianceCompletedNCT00293046Phase 3
• A Trial of the ALK Grass Tablet in Subjects With HayfeverCompletedNCT00227279Phase 3

← ALK-Abelló A/S overview and focus areas